Claims for Patent: 5,904,922

Summary for Patent: 5,904,922

Title:	Treatment with polyvalent antivenom containing immunoglobulin which is greater than 50% venom-reactive
Abstract:	Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin which is greater than fifty percent venom reactive. Purified polyvalent antivenom is derived from a first polyvalent antivenom having two or more monovalent subpopulations, and purified such that greater than fifty percent of the monovalent subpopulations are recovered by weight. The antivenoms can be horse or avian such as chicken antivenom. Chicken antivenom is obtained using a whole venom that is not glutaraldehyde pretreated, and the antivenom contains yolk immunoglobulin. Antivenoms are purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms of C. atrox, B. atrox, C. adamanteus and C. durissus terrificus. A combination of immobilized C. atrox and C. durissus terrificus whole venoms can substantially purify antivenom reactive with all four venoms. The antivenoms are intravenously injected to treat an envenomed mammalian subject.
Inventor(s):	Carroll; Sean B. (Cottage Grove, WI)
Assignee:	Ophidian Pharmaceuticals, Inc. (Madison, WI)
Application Number:	08/442,000
Patent Claims:	1. A method of treatment, comprising: a) providing a purified chicken antivenom in an aqueous solution in therapeutic amount that is intravenously injectable, wherein said antivenom is obtained from a host immunized with whole venom that is not glutaraldehyde pretreated and wherein said antivenom comprises yolk immunoglobulin of which greater than fifty percent is venom-reactive; and; b) intravenously injecting said chicken antivenom into at least one envenomed mammalian subject. 2. The method of claim 1 wherein said avian antivenom reacts with venom selected from the group consisting of Chordata, Arthropoda and Coelenterata venoms. 3. The method of claim 1 wherein said avian antivenom reacts with venom selected from the group consisting of snake venoms, spider venoms, scorpion venoms or jelly fish venoms. 4. The method of claim 1 wherein said avian antivenom reacts with venom selected from the group consisting of Crotalus scutulatus, Notechis scutatus, Acanthophis antarcticus, Oxyuranus scutellatus, Pseudonaja textilis, Pseudechis australis, Enhydrina schistosa, Ophiophagus hannah, Vipera ammodytes, Vipera aspis, Vipera berus, Vipera xanthina palestinae, Vipera lebetina, Cerastes cerastes, Cerastes vipera, Bitis arietans, Bitis gabonica, Vipera russelli, Echis carinatus, Trimeresurus flavoviridis, Agkistrodon halys, A. piscivorus, A. contortrix, Naja naja, Naja n. haje, Naja n. kaouthia, Naja n. oxiana, Naja n. sputatrix, Naja n. atra, Naja nivea, Naja nigrocollis, Hemachatus hemachatus, Dendroaspis angusticeps, Dendroaspis jamesonii, Dendroaspis polylepis, Dendroaspis viridis, Bungarus caerulus, Bungarus fasciatus, Bungarus multicinctus, Agkistrodon rhodostoma, Agkistrodon acutus, Bothrops atrox, Bothrops jararaca, Bothrops jararacussu, Bothrops alternatus, Lachesis muta, Micrurus corralus, Micrurus fulvius, Micrurus frontalis, Micrurus niagrocinctus, Leiurus guinguestriatus, Tityus serrulatus, Centruroides suffusus, Centruroides noxius, Centruroides sculpturatus, Androctonus australis, Buthotus judaicus, Buthus tamalus, Latrodectus mactans, Latrodectus hesperus, Loxosceles reclusa, and Chironex fleckeri. 5. The method of claim 1 wherein said avian antivenom reacts with C. atrox, B. atrox, C. adamanteus and C. durissus terrificus venoms. 6. A method of treatment, comprising: a) providing i) a purified polyvalent antivenom in an aqueous solution in therapeutic amount that is intravenously injectable, comprising immunoglobulin of which greater than fifty percent is venom-reactive, said purified antivenom being derived from a first polyvalen antivenom having two or more monovalent subpopulations, and being purified such that greater than fifty percent of said monvalent subpopulations are recovered by weight, ii) at least one envenomed mammalian subject; and b) intravenously injecting said polyvalent antivenom into said subject. 7. The method of claim 6 wherein said polyvalent antivenom is horse antivenom. 8. The method of claim 6 wherein said polyvalent antivenom reacts with venom selected from the group consisting of Chordata, Arthronoda and Coelenterata venoms. 9. The method of claim 6 wherein said polyvalent antivenon reacts with venom selected from the group consisting of snake venoms, spider venoms, scorpion venoms or jelly fish venoms. 10. The method of claim 6 wherein said polyvalent antivenom reacts with venom selected from the group consisting of Crotalus scutulatus, Notechis scutatus, Acanthophis antarcticus, Oxyuranus scutellatus, Pseudonala textilis, Pseudechis australis, Enhydrina schistosa, Ophiophagus hannah, Vipera ammodytes, Vipera aspis, Vipera berus, Vipera xanthina palestinae, Vipera lebetina, Cerastes cerastes, Cerastes vipera, Bitis arietans, Bitis gabonica, Vipera russelli, Echis carinatus, Trimeresurus flavoviridis, Agkistrodon halys, A. piscivorus, A. contortrix, Naja naja, Naja n. haje, Naja n. kaouthia, Naja n. oxiana, Naja n. sputatrix, Naja n. atra, Naja nivea, Naja nigrocollis, Hemachatus hemachatus, Dendroaspis angusticeps, Dendroaspis jamesonii, Dendroaspis polylepis, Dendroaspis viridis, Bungarus caerulus, Bungarus fasciatus, Bungarus multicinctus, Agkistrodon rhodostoma, Agkistrodon acutus, Bothrops atrox, Bothrops jararaca, Bothrops jararacussu, Bothrops alternatus, Lachesis muta, Micrurus corralus, Micrurus fulvius, Micrurus frontalis, Micrurus niagrocinctus, Leiurus guinguestriatus, Tityus serrulatus, Centruroides suffusus, Centruroides noxius, Centruroides sculpturatus, Androctonus australis, Buthotus judaicus, Buthus tamalus, Latrodectus mactans, Latrodectus hesperus, Loxosceles reclusa, and Chironex fleckeri venoms. 11. The method of claim 6 wherein said polyvalent antivenom reacts with C. atrox, B. atrox, C. adamanteus and C. durissus terrificus venoms. 12. A method of treatment, comprising: a) providing: i) an affinity purified antivenom capable of neutralizing both C. atrox and C. durissus terrificus venoms, and comprising immunoglobulin of which greater than fifty percent is venom-reactive, and ii) at least one envenomed mammalian subject, b) intravenously injecting said antivenom into said subject.

Details for Patent 5,904,922

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	LACTRODECTUS MACTANS	antivenin (latrodectus mactans)	For Injection	101062	02/13/1936		2016-05-18
Wyeth Pharmaceuticals Llc	MICRURUS FULVIUS	antivenin (micrurus fulvius)	For Injection	101099	08/28/1967		2016-05-18